benzyl [(1S,3R)-3-fluorocyclopentyl]carbamate | 932706-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl [(1S,3R)-3-fluorocyclopentyl]carbamate
• 英文别名: (1S,3R)-1-{[(benzyloxy)carbonyl]amino}-3-fluoro-cyclopentane；benzyl N-[(1S,3R)-3-fluorocyclopentyl]carbamate
• CAS: 932706-26-8
• 化学式: C₁₃H₁₆FNO₂
• 分子量: 237.274
• InChiKey: NDVBOSIQTJVVNB-NEPJUHHUSA-N

物化性质

• 沸点：
  371.3±41.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl [(1S,3R)-3-fluorocyclopentyl]carbamate 在 palladium hydroxide on carbon 氢气 、 盐酸 作用下， 以 甲醇 、 1,4-二氧六环 为溶剂， 20.0 ℃ 、101.3 kPa 条件下， 反应 20.0h， 生成 (1S,3R)-3-氟环戊烷-1-胺盐酸盐
  参考文献：
  名称：

  WO2007/37513

  摘要：

  公开号：
• 作为产物：
  描述：

  (1S,3S)-3-(((Benzyloxy)carbonyl)amino)cyclopentyl methanesulfonate 在 四丁基氟化铵 作用下， 以 水 、 乙腈 为溶剂， 反应 1.0h， 生成 benzyl [(1S,3R)-3-fluorocyclopentyl]carbamate
  参考文献：
  名称：

  WO2007/37513

  摘要：

  公开号：

文献信息

• Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20170073343A1

  公开（公告）日：2017-03-16

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R 1 , R 1a , R 1b , R 2 , R 4 , R 5 , R 6 , X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了新颖的咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啉衍生物的化合物(I)及其药学上可接受的盐，其中R1、R1a、R1b、R2、R4、R5、R6、X和Z如规范中所定义。该发明还涉及包含化合物(I)的药物组合物，以及利用这些化合物治疗与LRRK2相关的疾病，如神经退行性疾病包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds
  申请人：Ito Hirokatsu

  公开号：US20090275617A1

  公开（公告）日：2009-11-05

  Disclosed is an aryl-substituted nitrogen-containing heterocyclic compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof. This compound serves as nociceptin receptor antagonist and is useful as a pharmaceutical agent for treating diseases associated with a nociceptin receptor. (I) [in the formula, A 1 , A 2 and A 3 independently represent a carbon atom or a nitrogen atom, and one or two of A 1 , A 2 and A 3 represent a carbon atom; R 1 represents a lower alkyl group or the like; R 2 represents a phenyl group which may be substituted with a halogen atom or the like; R 3 represents a hydrogen atom, a lower alkyl group or the like; and R 4 represents a lower alkyl group or the like.]

  本发明公开了一种芳基取代的含氮杂环化合物，其化学式如下（I），或其药学上可接受的盐。该化合物作为伤害感受受体拮抗剂，并且可用作治疗与伤害感受受体相关的疾病的药物。 （I）[在该式中，A1，A2和A3独立地表示碳原子或氮原子，其中一个或两个A1，A2和A3表示碳原子；R1表示较低的烷基或类似物；R2表示苯基，其可以用卤素原子或类似物取代；R3表示氢原子，较低的烷基或类似物；R4表示较低的烷基或类似物。]
• ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1935881A1

  公开（公告）日：2008-06-25

  Disclosed is an aryl-substituted nitrogen-containing heterocyclic compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof. This compound serves as nociceptin receptor antagonist and is useful as a pharmaceutical agent for treating diseases associated with a nociceptin receptor. (I) [in the formula, A1, A2 and A3 independently represent a carbon atom or a nitrogen atom, and one or two of A1, A2 and A3 represent a carbon atom; R1 represents a lower alkyl group or the like; R2 represents a phenyl group which may be substituted with a halogen atom or the like; R3 represents a hydrogen atom, a lower alkyl group or the like; and R4 represents a lower alkyl group or the like.]

  本发明公开了由下式(I)代表的芳基取代的含氮杂环化合物或其药学上可接受的盐。该化合物可作为痛觉素受体拮抗剂，可用于治疗与痛觉素受体相关的疾病。(I) [式中，A1、A2 和 A3 分别代表碳原子或氮原子，A1、A2 和 A3 中的一个或两个代表碳原子；R1 代表低级烷基或类似基团；R2 代表可被卤素原子或类似基团取代的苯基；R3 代表氢原子、低级烷基或类似基团；R4 代表低级烷基或类似基团。］
• Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
  申请人：Pfizer Inc.

  公开号：US10039753B2

  公开（公告）日：2018-08-07

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了式 (I) 的新型咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物及其药学上可接受的盐类 其中 R1、R1a、R1b、R2、R4、R5、R6、X 和 Z 如说明书中所定义。本发明还涉及包含式（I）化合物的药物组合物，以及该化合物在治疗与 LRRK2 有关的疾病中的用途，如神经退行性疾病，包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP3350178B1

  公开（公告）日：2021-10-20